Scope
NICE NG133 distinguishes chronic hypertension, gestational hypertension and pre-eclampsia across pregnancy, birth and postnatal care. The selected pathway covers aspirin eligibility, proteinuria assessment, treatment and escalation, critical-care priorities and follow-up; maternal symptoms and organ dysfunction remain central rather than relying on a blood-pressure or urine result alone.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognize risk and assess proteinuria in context
- Advise immediate assessment for severe headache, visual disturbance, severe pain below the ribs, vomiting or sudden swelling of the face, hands or feet during pregnancy; these may be pre-eclampsia symptoms. [1]
- Advise aspirin 75–150 mg daily from 12 weeks until birth when any high-risk factor is present: previous hypertensive pregnancy disease, chronic kidney disease, autoimmune disease such as lupus or antiphospholipid syndrome, type 1 or 2 diabetes, or chronic hypertension. [1]
- Also advise aspirin 75–150 mg daily from 12 weeks until birth with more than one moderate risk factor: nulliparity, age ≥40, pregnancy interval >10 years, booking BMI ≥35 kg/m2, family history of pre-eclampsia or multifetal pregnancy. [1]
- Interpret proteinuria with the full clinical assessment. After a dipstick result of 1+ or more, quantify albumin:creatinine or protein:creatinine ratio; do not routinely use a 24-hour collection or the first morning urine void for quantification. [1]
- Use a protein:creatinine threshold of 30 mg/mmol for significant proteinuria, or albumin:creatinine 8 mg/mmol in a hypertensive pregnant patient. If an elevated result leaves diagnostic uncertainty, consider a new sample with clinical review. [1]
- Suspected pre-eclampsia warrants assessment beyond urine protein: new hypertension after 20 weeks may coexist with maternal renal, liver, neurological or haematological dysfunction, or uteroplacental dysfunction, without proteinuria. [1]
Distinguish stable treatment from urgent escalation
- Review chronic hypertension with a pregnancy specialist. Stop ACE inhibitors or ARBs promptly after pregnancy notification, preferably within 2 working days, and offer an alternative; discuss alternatives before a planned pregnancy. [1]
- For untreated chronic hypertension, start treatment at sustained systolic ≥140 or diastolic ≥90 mmHg and aim for 135/85 mmHg. Existing pregnancy-safe treatment can continue unless sustained systolic is <110, diastolic <70, or symptomatic hypotension develops. [1]
- For chronic hypertension, consider labetalol, nifedipine if unsuitable, then methyldopa if both are unsuitable. For pre-eclampsia, offer labetalol with source-specified alternatives when unsuitable, considering prior treatment, adverse effects, fetal risk and patient preference. [1]
- Gestational hypertension needs a trained secondary-care assessment. Offer PLGF-based testing to help rule out suspected pre-eclampsia between 20 weeks and 36 weeks 6 days, including suspected superimposed disease in chronic hypertension. [1]
- In pre-eclampsia, admit for maternal or fetal concerns, including sustained systolic pressure ≥160 mmHg, worsening laboratory findings, impending eclampsia or pulmonary oedema, or fetal compromise. Clinical concern matters even without severe hypertension. [1]
- Consider fullPIERS or PREP-S to support pre-eclampsia place-of-care and intervention decisions. PREP-S is intended only up to 34 weeks; fullPIERS can be used throughout pregnancy. Neither predicts infant outcomes. [1]
- In chronic hypertension, obtain growth, amniotic-fluid and umbilical Doppler scans at 28, 32 and 36 weeks. In pre-eclampsia or severe gestational hypertension, obtain CTG at diagnosis and repeat for changed fetal movement, bleeding, abdominal pain or maternal deterioration. [1]
Plan birth and manage severe disease
- For chronic or gestational hypertension below 160/110 mmHg, do not plan birth before 37 weeks without another medical indication. After 37 weeks, agree timing with the patient and senior obstetrician. [1]
- For pre-eclampsia, document individual maternal/fetal early-birth thresholds. Examples include uncontrolled pressure despite ≥3 appropriate antihypertensive classes, progressive organ or platelet deterioration, persistent neurological features, abruption or concerning fetal Doppler/CTG findings. [1]
- In pre-eclampsia from 37 weeks, initiate birth within 24–48 hours. Earlier pregnancy generally requires surveillance unless early-birth indications arise, with gestation-appropriate corticosteroids and magnesium considered under the preterm-birth guidance. [1]
- In critical care, treat severe hypertension immediately during pregnancy or after birth with oral/intravenous labetalol, oral nifedipine or intravenous hydralazine, and monitor maternal and fetal response to adjust treatment. [1]
- Give intravenous magnesium sulfate for eclampsia in a critical-care patient with severe hypertension or severe pre-eclampsia. In critical care, consider it for severe pre-eclampsia with birth planned within 24 hours. Also consider it when severe pre-eclampsia includes ongoing or recurring severe headache, visual scotomata, nausea or vomiting, epigastric pain, oliguria with severe hypertension, or progressively rising creatinine or transaminases or falling platelets. [1]
- For eclampsia, do not substitute diazepam or phenytoin for magnesium sulfate. In severe pre-eclampsia, restrict maintenance fluid to 80 mL/hour unless ongoing losses such as haemorrhage require otherwise; do not use dexamethasone or betamethasone to treat HELLP syndrome. [1]
Continue surveillance and provide a handover plan
- After gestational hypertension or pre-eclampsia in previously untreated patients, start antihypertensive treatment at blood pressure ≥150/100 mmHg. For treated postnatal pre-eclampsia, consider dose reduction below 140/90 and reduce below 130/80 mmHg. [1]
- After pre-eclampsia, transfer to community care only when symptoms have resolved, blood pressure is ≤150/100 mmHg with or without treatment, AND blood tests are stable or improving. Provide a written monitoring, treatment-adjustment and referral plan. [1]
- Stop methyldopa within 2 days after birth and change treatment if necessary. Postnatal enalapril is offered with maternal renal-function and potassium monitoring; adapt treatment to breastfeeding, avoiding diuretics and ARBs where possible during breastfeeding. [1]
- Offer all patients after pre-eclampsia medical review at 6–8 weeks, with urine testing. If proteinuria remains ≥1+, review kidney function at 3 months and consider specialist kidney assessment if abnormal. [1]
- Explain that hypertensive pregnancy disorders increase later hypertension and cardiovascular risk. Discuss smoking avoidance, healthy lifestyle and weight, and consider pre-pregnancy counselling after pre-eclampsia or hypertension leading to birth before 34 weeks. [1]
Limitations and use
- This is not a complete emergency prescription or every maternal/fetal monitoring schedule. Acute drug dosing, renal adjustment, magnesium toxicity monitoring and contraindications require the full local obstetric critical-care protocol. Treatment formulation and breastfeeding decisions require individual review. The selected birth thresholds do not override deterioration or other obstetric indications.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Hypertension in pregnancy: diagnosis and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 25 June 2019
- Publisher’s latest update
- 17 April 2023
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.